Clinical trials: Schizophrenia Disorders
Schizophrenia Disorder, Schizoaffecitve Disorder
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
The study investigates whether a virtual reality-based mindfulness based intervention can reduce impulsive aggression in individuals with schizophrenia or schizoaffective disorder.
- Conditions
- Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
- Trial name
- NCT07434479
- Testing
- Mindfulness-Based Virtual Reality Intervention
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia, Electroconvulsive Therapy
ECT in Ultra-resistant Schizophrenia
The effects of the ECT in schizophrenia ultra-resistant were studied in short times (4-6 months in most studies with follow-up).
- Trial name
- SURECT (NCT03542903)
- Testing
- Electroconvulsive therapy
- Where
- 10 sites in France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier du Rouvray
Schizophrenia
Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan
This proposal responds to Request for Applications RFA-MH-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the National Institute of Mental Health (NIMH) Human Genetics…
- Trial name
- NCT01249079
- Testing
- No intervention would be provided in this research
- Where
- Taiwan
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Schizophrenia
Modulation of Repetitive Transcranial Magnetic Stimulation on Hippocampal Neurogenesis and Functional Network in Patients With Schizophrenia
Based on the hypothesis that high-frequency repetitive transcranial magnetic stimulation(rTMS) on the right dorsolateral prefrontal cortex(DLPFC) and left parietal cortex(LPC) could normalise cognitive abnormalities by promoting…
- Trial name
- NCT03608462
- Testing
- repetitive transcranial magnetic stimulation(DLPFC), repetitive transcranial magnetic stimulation(LPC)
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Cognition, Functioning and Quality of Life
People affected by schizophrenia often experience poor concentration, lapses in memory and difficulty with completing tasks; and this set of problems are known as neuro-cognitive deficits.
- Trial name
- NCT00182442
- Testing
- Olanzapine & Quetiapine
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Hamilton Health Sciences Corporation
Schizophrenia
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
- Trial name
- NCT00487942
- Testing
- armodafinil
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cephalon
Schizophrenia
Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia
This study aims to explore the objective markers concerning schizophrenia risk and functional outcome from multiple dimensions such as multi-omics including genomics, proteomics, metabolomics, electrophysiology, imaging…
- Trial name
- NCT07102069
- Where
- China
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Tianjin Anding Hospital
Anxiety, Depression
The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.
The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.
- Conditions
- Anxiety, Depression, Obsessive-compulsive Disorder, Personality Disorder
- Trial name
- RAKGEOCBT (NCT06993662)
- Testing
- Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.
- Where
- Greece
- Volunteers
- 107 people
- Sponsor
- Rakitzi, Stavroula
Cognitive Deficits in Schizophrenia
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01095562
- Testing
- ABT-126
- Where
- 23 sites in United States
- Volunteers
- 207 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Schizophrenia Spectrum Disorder (SSD)
Virtual Group Fitness and Nutrition Intervention for Individuals With Psychosis
Individuals with schizophrenia spectrum disorder (SSD) often face unique barriers that limit the development of long-lasting lifestyle changes.
- Trial name
- NCT04783246
- Testing
- Group Fitness, Nutrition education
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Boston Medical Center
Schizophrenia
rTMS Treatment for Positive and Negative Symptoms of Schizophrenia
This study will examine the effects of rTMS on the negative and positive symptoms of schizophrenia using 2 treatments in sequence applied to related brain areas.
- Trial name
- NCT03413527
- Testing
- rTMS
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Schizophrenia
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?
The investigators want to try to improve information processing in schizophrenic patients via pharmacological intervention. The hypothesis is that decreased noradrenergic activity will normalize information processing (PPI, P50…
- Trial name
- NCT00206986
- Testing
- clonidine
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia
This study is a confirmatory, double-blind, placebo-controlled randomized clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder.
- Trial name
- NCT07592169
- Testing
- EEG Neurofeedback
- Volunteers
- 104 people
- Sponsor
- University of California, San Diego
Schizophrenia Prodrome
Ethyl-EPA Treatment of Prodromal Patients
This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
- Trial name
- NCT00634361
- Testing
- ethyl-eicosapentaenoic acid
- Volunteers
- 7 people
- Sponsor
- Yale University
Metabolic Syndrome, Diabetes
Metabolic Profile and Anthropometric Changes in Schizophrenia
"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "
- Conditions
- Metabolic Syndrome, Diabetes, Obesity
- Trial name
- MetS (NCT00534183)
- Testing
- Olanzapine, Risperidone, Haloperidol
- Where
- India
- Volunteers
- 2,006 people
- Sponsor
- Central Institute of Psychiatry, Ranchi, India
Schizophrenia, Bipolar I Disorder
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.
- Trial name
- ANCHOR 150 (NCT00227305)
- Testing
- quetiapine fumarate
- Where
- 48 sites in United States, India and 7 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Prodromal Schizophrenia, Psychosis
Feasibility Trial of a Lifestyle Intervention for CHR-P
The present study will assess the feasibility and social validity of an adjunctive health promotion group for youth and clinical high risk for psychosis (CHR-P).
- Conditions
- Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
- Trial name
- NCT05532683
- Testing
- Health Behaviors Group
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, Los Angeles
Psychotic Disorders, Psychosis
Semantic and Syntactic Computerized Analysis of Free Speech
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic…
- Conditions
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders, Schizophrenia Prodromal
- Trial name
- ASESID (NCT03525054)
- Where
- 3 sites in France
- Volunteers
- 215 people
- Sponsor
- University Hospital, Brest
Schizophrenia, Schizoaffective Disorder
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
The objective of the study is to evaluate the efficacy of raloxifene compared to placebo, as add-on to anti-psychotics in the treatment of post menopausal patients with schizophrenia.
- Trial name
- RAL-S-01 (NCT01280305)
- Testing
- raloxifene
- Where
- 13 sites in Israel, Romania
- Volunteers
- 200 people
- Sponsor
- Sheba Medical Center